Inventor · disambiguated record
Peter Lionel Spargo
Also filed as: SPARGO PETER · SPARGO PETER LIONEL
15 granted patents·11 pending applications·175 citations·filing 1995–2025
93Inventor score
Files withVERONA PHARMA PLC19FOREST LAB HOLDINGS LTD2FOREST LABORATORIES HOLDINGS LTD2PFIZER2DEDHIYA MAHENDRA G1
Top patents by PatentIndex Score
26 records- 0194US12168011B2Formulation production processVERONA PHARMA PLC·Filed 2024·Granted Dec 17, 2024·3 cites·25 claims
- 0294US9062053B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LAB HOLDINGS LTD·Filed 2014·Granted Jun 23, 2015·15 cites·9 claims
- 0394US8835455B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LAB HOLDINGS LTD·Filed 2013·Granted Sep 16, 2014·15 cites·10 claims
- 0493US8471025B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltDEDHIYA MAHENDRA G·Filed 2010·Granted Jun 25, 2013·26 cites·34 claims
- 0592US12251384B1Particulate compositionVERONA PHARMA PLC·Filed 2024·Granted Mar 18, 2025·1 cites·26 claims
- 0692US12194045B1Particulate compositionVERONA PHARMA PLC·Filed 2024·Granted Jan 14, 2025·1 cites·22 claims
- 0790US10710998B2Compound and processVERONA PHARMA PLC·Filed 2017·Granted Jul 14, 2020·6 cites·31 claims
- 0890US9956171B2Liquid inhalation formulation comprising RPL554VERONA PHARMA PLC·Filed 2015·Granted May 1, 2018·12 cites·18 claims
- 0989US5750707ASeparation of the enantiomers of amlodipine via their diastereomeric tartratesPFIZER·Filed 1995·Granted May 12, 1998·42 cites·4 claims
- 1088US10463665B2Salt of a pyrimido[6,1-A]isoquinolin-4-one compoundVERONA PHARMA PLC·Filed 2016·Granted Nov 5, 2019·9 cites·12 claims
- 1187US10945950B2Liquid inhalation formulation comprising RPL554VERONA PHARMA PLC·Filed 2018·Granted Mar 16, 2021·7 cites·12 claims
- 1286US11491155B2Salt of a pyrimido[6,1-A]isoquinolin-4-one compoundVERONA PHARMA PLC·Filed 2019·Granted Nov 8, 2022·6 cites·16 claims
- 1386US6046338ASeparation of the enantiomers of amlodipine via their diastereomeric tartratesPFIZER·Filed 1998·Granted Apr 4, 2000·32 cites·9 claims
- 1484US12409180B2Formulation production processVERONA PHARMA PLC·Filed 2024·Granted Sep 9, 2025·0 cites·14 claims
- 1576US2025319090A1Formulation production processVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 1673US2025049781A1Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalationVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 1767US2024382489A1Liquid pharmaceutical compositionVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 1866US2025170135A1Particulate compositionVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 1963US2017210742A1Novel crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LABORATORIES HOLDINGS LTD·Filed 2017·Application pending·0 cites
- 2063US2024165023A1Liquid pharmaceutical compositionVERONA PHARMA PLC·Filed 2024·Application pending·0 cites
- 2161US9580424B2Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium saltFOREST LABORATORIES HOLDINGS LTD·Filed 2015·Granted Feb 28, 2017·0 cites·54 claims
- 2253US2023112220A1Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolateVERONA PHARMA PLC·Filed 2021·Application pending·0 cites
- 2351US2021379053A1Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalationVERONA PHARMA PLC·Filed 2019·Application pending·0 cites
- 2451US2022265549A1Pharmaceutical composition comprising ensifentrineVERONA PHARMA PLC·Filed 2020·Application pending·0 cites
- 2546US2025249008A1Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary diseaseVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
- 2645US2025249007A1Pharmaceutical compositions of ensifentrine for chronic obstructive pulmonary diseaseVERONA PHARMA PLC·Filed 2025·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →